Although the CP-CML depends on BCR-ABL1, the progression of acute blast crisis is mediated by additional genetic changes and mouse models of CML are needed to develop therapies for unresponsive patients to TKIs [232]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.